Physiology of Menopause — MCQs
Which of the following is a beneficial effect of hormone replacement therapy in early menopause?
A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?
Levels of which of the following hormones are increased in postmenopausal women:
35 yr old with 4 months amenorrhea with increased FSH, decreased estrogen. What is the diagnosis?
Which of the following statements about the postmenopausal state is false?
In the transition from a Graafian follicle to a functional corpus luteum, which of the following cellular events occurs?
Gonadotrophins remain elevated after menopause for :
Menopause is associated with the following except:
Which of the following is NOT characteristic of menopause?
Physiology of Menopause Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is a beneficial effect of hormone replacement therapy in early menopause?
- A. Increased Endothelin
- B. Increased TNF-α
- C. Increased Nitric oxide (Correct Answer)
- D. Decreased COX-2
Explanation: ***Increased Nitric oxide*** - **Estrogen** in HRT increases the production and bioavailability of **nitric oxide (NO)** by upregulating endothelial nitric oxide synthase (eNOS). - Increased NO leads to **vasodilation**, contributing to cardiovascular benefits and improved endothelial function. *Increased Endothelin* - **Endothelin-1** is a potent vasoconstrictor, and increased levels are generally associated with **endothelial dysfunction** and cardiovascular risk. - HRT, particularly estrogen, tends to decrease endothelin-1 levels or counteract its effects, leading to beneficial vascular responses. *Increased TNF-α* - **Tumor Necrosis Factor-alpha (TNF-α)** is a pro-inflammatory cytokine, and elevated levels are linked to chronic inflammation and increased risk of various diseases. - HRT, especially estrogen, typically has **anti-inflammatory effects**, potentially reducing TNF-α levels or mitigating its inflammatory actions. *Decreased COX-2* - **Cyclooxygenase-2 (COX-2)** is an enzyme involved in inflammation and pain pathways; its decrease is generally anti-inflammatory. - However, the primary beneficial vascular effect of HRT is not through direct inhibition of COX-2 but rather through mechanisms like increasing nitric oxide.
Question 2: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?
- A. Estrogen plus progesterone (Correct Answer)
- B. Citalopram
- C. Estrogen
- D. Levothyroxine
Explanation: ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.
Question 3: A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?
- A. Premature ovarian insufficiency (Correct Answer)
- B. Menopause
- C. Late menopause
- D. Perimenopause
Explanation: ***Premature ovarian insufficiency (POI)*** - The patient's age (35 years) combined with 4 months of **amenorrhea**, increased **FSH** and **LH**, and decreased **estrogen** is characteristic of premature ovarian insufficiency (also called premature ovarian failure). - The hormonal profile (**hypergonadotropic hypogonadism**) indicates ovarian failure occurring before the age of **40 years**, which defines POI. - POI affects approximately **1% of women under 40** and can present with amenorrhea, infertility, and symptoms of estrogen deficiency. *Menopause* - Menopause is diagnosed after **12 consecutive months of amenorrhea** in a woman, typically occurring around age **51 years** (natural menopause). - While the hormonal profile of elevated FSH/LH and low estrogen is consistent with menopause, the patient's **age of 35 years** and **only 4 months of amenorrhea** do not meet the criteria for natural menopause. *Late menopause* - Late menopause refers to menopause occurring at a later age than average, typically after age **55 years**. - This diagnosis is completely inconsistent with the patient's age of 35 years. *Perimenopause* - Perimenopause is the transitional phase leading up to menopause, characterized by **irregular menstrual cycles** and **fluctuating hormone levels**. - While FSH levels may be elevated at times, perimenopause typically shows **variable hormone levels** rather than the sustained pattern of high FSH/LH with low estrogen seen in this case. - The **sustained amenorrhea** and pronounced hormonal shifts indicate ovarian failure (POI) rather than perimenopausal transition.
Question 4: Levels of which of the following hormones are increased in postmenopausal women:
- A. FSH (Correct Answer)
- B. Estrogen
- C. Progesterone
- D. Cortisol
Explanation: ***FSH*** - In postmenopausal women, the **ovaries cease to produce estrogen and progesterone**, leading to a loss of negative feedback on the hypothalamus and pituitary gland. - This results in a **significant increase in the secretion of Follicle-Stimulating Hormone (FSH)** and Luteinizing Hormone (LH) from the anterior pituitary as the body attempts to stimulate ovarian function. *Estrogen* - Estrogen levels **decrease significantly** during menopause as the ovaries stop producing ovarian follicles and ultimately cease ovulation. - The drop in estrogen is responsible for many menopausal symptoms, such as **hot flashes and vaginal dryness**. *Progesterone* - Progesterone levels also **decrease substantially** after menopause, as its primary source is the corpus luteum formed after ovulation, which no longer occurs. - The decline in progesterone contributes to the **irregular menstrual cycles** leading up to and during menopause. *Cortisol* - **Cortisol levels are not directly affected by menopause** in the same dramatic way as sex hormones. - Cortisol is a stress hormone produced by the adrenal glands, and its levels are primarily regulated by the **hypothalamic-pituitary-adrenal (HPA) axis**, which is distinct from the reproductive axis.
Question 5: 35 yr old with 4 months amenorrhea with increased FSH, decreased estrogen. What is the diagnosis?
- A. Premature ovarian failure (Correct Answer)
- B. Pituitary dysfunction
- C. Hypothalamic dysfunction
- D. Polycystic Ovary Syndrome
Explanation: ***Premature ovarian failure*** - The combination of **amenorrhea** for 4 months in a 35-year-old, with **increased FSH** and **decreased estrogen**, is characteristic of premature ovarian failure, indicating the ovaries are no longer responding to FSH stimulation. - This condition signifies the cessation of ovarian function before the age of 40, leading to menopausal symptoms and infertility. *Pituitary dysfunction* - Pituitary dysfunction might lead to **decreased FSH** (hypogonadotropic hypogonadism) due to insufficient stimulation of the ovaries, not increased FSH. - In cases of pituitary adenomas, increased prolactin can cause amenorrhea, but FSH would not be elevated in the manner described. *Hypothalamic dysfunction* - Hypothalamic dysfunction, such as **functional hypothalamic amenorrhea**, typically presents with **low or normal FSH and LH levels** (hypogonadotropic hypogonadism) due to reduced GnRH pulsatility. - This condition is often associated with stress, excessive exercise, or low body weight, and would not cause elevated FSH as seen here. *Polycystic Ovary Syndrome* - **Polycystic Ovary Syndrome (PCOS)** is characterized by **anovulation**, resulting in amenorrhea or oligomenorrhea, but typically involves **elevated androgens** and a **high LH-to-FSH ratio**, with FSH levels generally normal or low, and estrogen levels often normal or slightly elevated. - It would not present with simultaneously high FSH and low estrogen, which points to ovarian failure rather than anovulation with intact ovarian reserve.
Question 6: Which of the following statements about the postmenopausal state is false?
- A. High FSH
- B. Low LH (Correct Answer)
- C. Low estrogen
- D. High androgen
Explanation: ***Low LH*** - This statement is **FALSE** because **LH (luteinizing hormone) levels are markedly elevated** in postmenopausal women. - The drop in ovarian estrogen production removes the **negative feedback** on the pituitary, leading to **increased LH and FSH secretion**. - Both gonadotropins (LH and FSH) are characteristically **high in postmenopause**. *High FSH* - This statement is true; **FSH (follicle-stimulating hormone) levels are markedly elevated** in postmenopausal women. - The elevated FSH is a direct consequence of the **lack of negative feedback** from inhibin and estrogen produced by the ovaries. *Low estrogen* - This statement is true; **estrogen levels plummet significantly** after menopause due to the **cessation of ovarian follicular activity**. - This **estrogen deficiency** is responsible for many postmenopausal symptoms, such as hot flashes, vaginal atrophy, and bone loss. *High androgen* - While androgens are still produced by the adrenal glands and ovaries postmenopause, their **absolute levels also decline with age**. - The statement is somewhat ambiguous, but androgens do **not increase** in absolute terms; rather, the **estrogen-to-androgen ratio changes** because estrogen falls more dramatically.
Question 7: In the transition from a Graafian follicle to a functional corpus luteum, which of the following cellular events occurs?
- A. Granulosa cells begin to express estrogen receptors
- B. Granulosa cells begin to express LH receptors (Correct Answer)
- C. Theca cells begin to express androgen receptors
- D. Granulosa cells begin to express progesterone receptors
Explanation: ***Granulosa cells begin to express LH receptors*** - During the late follicular phase, under **FSH** stimulation, **granulosa cells** in the developing Graafian follicle acquire **LH receptors**. - This acquisition of LH receptors is essential for the transition to a corpus luteum, as it enables the **LH surge** to trigger ovulation and subsequently stimulate **luteinization** and **progesterone production** by the corpus luteum. - While the initial expression occurs before ovulation, the functional significance becomes apparent during the transformation to the corpus luteum, making this the most critical receptor-related event in this transition among the given options. *Granulosa cells begin to express estrogen receptors* - Granulosa cells already express **estrogen receptors** in early follicular stages, which are essential for their proliferation and **aromatase synthesis**. - Estrogen receptor expression is characteristic of developing follicles throughout folliculogenesis, not specifically associated with corpus luteum formation. *Theca cells begin to express androgen receptors* - **Theca cells** produce **androgen precursors** (androstenedione, testosterone) under LH stimulation during the follicular phase, which granulosa cells convert to estrogen. - While theca cells contribute to the corpus luteum (theca-lutein cells), androgen receptor expression is not the primary defining cellular event of this transition. *Granulosa cells begin to express progesterone receptors* - The corpus luteum is the major source of **progesterone** in the luteal phase, but granulosa cells do not significantly upregulate progesterone receptors as part of their luteinization. - The key functional change is the cells' ability to *produce* large amounts of progesterone in response to LH, not increased progesterone receptor expression.
Question 8: Gonadotrophins remain elevated after menopause for :
- A. Rest of life (Correct Answer)
- B. 5 years
- C. 10 years
- D. 2 years
Explanation: **Correct Answer: Rest of life** - Following menopause, the ovaries cease to produce significant amounts of **estrogen** and **progesterone**. - This lack of negative feedback on the **hypothalamic-pituitary axis** leads to persistently elevated levels of **gonadotropins (FSH and LH)** throughout the remainder of a woman's life. - The **ovarian failure** and subsequent lack of estrogen production are irreversible, resulting in permanent elevation of gonadotropins. *Incorrect: 5 years* - While gonadotropin levels are high during this period, they do not normalize or significantly decrease after 5 years post-menopause. - The hormonal changes of menopause are permanent, not transient. *Incorrect: 10 years* - Similar to the 5-year period, gonadotropin levels remain elevated and do not revert to pre-menopausal levels after 10 years. - The physiological shift is permanent. *Incorrect: 2 years* - The initial years immediately following menopause (**perimenopause** and early post-menopause) are marked by significantly elevated gonadotropin levels. - However, these levels remain high indefinitely, indicating a permanent physiological shift, not a temporary elevation that resolves after only 2 years.
Question 9: Menopause is associated with the following except:
- A. Delusion (Correct Answer)
- B. Loss of libido
- C. Ischemic heart disease
- D. Osteoporosis
Explanation: ***Delusion*** - Delusions are a feature of **psychotic disorders** and are not directly associated with the physiological changes of menopause. - While menopause can affect mood and cognitive function, it does not typically cause **psychotic symptoms** like delusions. *Loss of libido* - The decline in **estrogen levels** during menopause can lead to vaginal dryness and discomfort during intercourse, which can contribute to a loss of libido. - Hormonal changes also directly impact sexual desire, making it a common menopausal symptom. *Ischemic heart disease* - Estrogen has a **cardioprotective effect**, and its decline after menopause increases women's risk for **ischemic heart disease**. - The absence of estrogen contributes to changes in lipid profiles and endothelial function, predisposing women to cardiovascular events. *Osteoporosis* - Estrogen plays a crucial role in maintaining **bone density**, and its reduction during menopause accelerates bone loss. - This loss of bone mass significantly increases the risk of **osteoporosis** and fractures in postmenopausal women.
Question 10: Which of the following is NOT characteristic of menopause?
- A. Systemic vasomotor instability may be present
- B. There may be an increase in FSH secretion by the pituitary gland
- C. There is a marked decrease in adrenal cortical estrogen secretion (Correct Answer)
- D. There is a decrease in skin elasticity
Explanation: ***There is a marked decrease in adrenal cortical estrogen secretion*** - While **estrogen levels** do decrease significantly in **menopause**, the primary source of this drop is the **ovaries**, not the adrenal cortex. - The adrenal cortex primarily produces **androgens** (like DHEA), which can be converted to estrogens in peripheral tissues, but it is not the main source of estrogen and its secretion does not markedly decrease during menopause. *Systemic vasomotor instability may be present* - This is a hallmark symptom of **menopause**, manifesting as **hot flashes** and night sweats due to erratic thermoregulation. - It arises from **estrogen withdrawal**, which affects the hypothalamus's control over body temperature. *There may be an increase in FSH secretion by the pituitary gland* - As ovarian function declines and **estrogen production** decreases, the negative feedback on the **hypothalamic-pituitary axis** is reduced. - This leads to a compensatory **increase in GnRH** from the hypothalamus and subsequently elevated **FSH** and **LH** from the pituitary gland. *There is a decrease in skin elasticity* - **Estrogen deficiency** contributes to reduced collagen synthesis and dermal hydration, leading to **decreased skin elasticity** and increased wrinkles. - This is a common and characteristic dermatological change observed in menopausal women.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free